Biotech and Medical Tech Stocks Directory (Updated for 2025)

Aadi Bioscience, Inc. (NASDAQ: AADI)

• Description: Aadi Bioscience, Inc. is a biopharmaceutical company developing precision therapies for genetically defined cancers. Its lead product, FYARRO (sirolimus protein-bound particles), is approved for advanced malignant PEComa, with ongoing trials targeting mTOR-driven tumors in 2025.

Abeona Therapeutics Inc. (NASDAQ: ABEO)

• Description: Abeona Therapeutics Inc. is a clinical-stage company focused on gene and cell therapies for serious diseases. Its lead candidate, pz-cel (prademagene zamikeracel), targets recessive dystrophic epidermolysis bullosa (RDEB) and is in late-stage development with potential approval in 2025.

Acasti Pharma Inc. (NASDAQ: ACST)

• Description: Acasti Pharma Inc. is a late-stage biopharma developing therapies for rare and orphan diseases. GTX-104, an IV nimodipine for subarachnoid hemorrhage, completed a successful Phase 3 trial in 2025, advancing toward U.S. regulatory submission.

Accuray Incorporated (NASDAQ: ARAY)

• Description: Accuray Incorporated develops robotic radiosurgery systems like CyberKnife and TomoTherapy, providing precise radiation treatments for cancer and neurological conditions, with over 1,000 systems installed globally.

Acorda Therapeutics, Inc. (NASDAQ: ACOR)

• Description: Acorda Therapeutics, Inc. focuses on neurological disorders, marketing INBRIJA (levodopa inhalation powder) for Parkinson's disease and FAMPYRA (fampridine) for MS-related walking issues, with a pipeline exploring new CNS indications.

Aethlon Medical, Inc. (NASDAQ: AEMD)

• Description: Aethlon Medical, Inc. develops the Hemopurifier, a device to remove viruses and exosomes from blood. With FDA Breakthrough Device designations for cancer and viral infections, it's advancing clinical trials in 2025.

Affimed N.V. (NASDAQ: AFMD)

• Description: Affimed N.V. is a clinical-stage immuno-oncology company developing innate cell engagers (ICE). Its lead candidate, AFM13, targets CD30-positive lymphomas and is in Phase 2 trials, with combination therapies progressing.

AgeX Therapeutics, Inc. (NYSE American: AGE)

• Description: AgeX Therapeutics, Inc. focuses on regenerative medicine using its UniverCyte™ platform for allogeneic cell therapies. It targets age-related degenerative diseases, with preclinical programs nearing clinical stages in 2025.

Aileron Therapeutics, Inc. (NASDAQ: ALRN)

• Description: Aileron Therapeutics, Inc. develops precision medicines for p53-mutated cancers. ALRN-6924, a chemoprotective agent, is in trials to reduce chemotherapy toxicity, with data expected in 2025.

Alimera Sciences, Inc. (NASDAQ: ALIM)

• Description: Alimera Sciences, Inc. specializes in retinal health, marketing ILUVIEN (fluocinolone acetonide intravitreal implant) for diabetic macular edema and uveitis, expanding its global footprint in 2025.

AlloVir, Inc. (NASDAQ: ALVR)

• Description: AlloVir, Inc. develops allogeneic T-cell therapies for viral diseases in immunocompromised patients. Its multi-virus targeting candidates are in Phase 3 trials post-transplantation, with results anticipated in 2025.

Alpha Tau Medical Ltd. (NASDAQ: DRTS)

• Description: Alpha Tau Medical Ltd. develops Alpha DaRT™ (Diffusing Alpha-emitters Radiation Therapy) for solid tumors. Clinical trials for skin, breast, and pancreatic cancers continue, offering targeted radiotherapy advancements.

Alterity Therapeutics Limited (NASDAQ: ATHE)

• Description: Alterity Therapeutics Limited focuses on neurodegenerative diseases, with ATH434 in Phase 2 trials for Multiple System Atrophy (MSA), aiming to alter disease progression using novel small molecules.

Alto Neuroscience, Inc. (NYSE: ANRO)

• Description: Alto Neuroscience, Inc. develops precision psychiatry treatments using AI-driven biomarkers. Its pipeline for depression and PTSD is advancing through clinical stages, with key data readouts in 2025.

Amicus Therapeutics, Inc. (NASDAQ: FOLD)

• Description: Amicus Therapeutics, Inc. develops therapies for rare diseases, marketing Galafold (migalastat) for Fabry disease and advancing AT-GAA for Pompe disease, with global approvals expanding in 2025.

AngioDynamics, Inc. (NASDAQ: ANGO)

• Description: AngioDynamics, Inc. designs medical devices for vascular access and oncology, with NanoKnife for irreversible electroporation gaining traction in minimally invasive cancer treatments in 2025.

Anixa Biosciences, Inc. (NASDAQ: ANIX)

• Description: Anixa Biosciences, Inc. focuses on cancer diagnostics and immunotherapy. Cchek™ detects early-stage cancer, while its CAR-T therapy for ovarian cancer progresses in clinical trials, targeting milestones in 2025.

Annaly Capital Management, Inc. (NYSE: NLY)

• Description: Annaly Capital Management, Inc., a diversified capital manager, invests in healthcare and biotech through subsidiaries, supporting medical tech innovations as part of its broader portfolio in 2025.

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)

• Description: Apellis Pharmaceuticals, Inc. targets the complement system, marketing SYFOVRE (pegcetacoplan) for geographic atrophy and EMPAVELI for PNH, with further indications advancing in trials.

Applied Therapeutics, Inc. (NASDAQ: APLT)

• Description: Applied Therapeutics, Inc. develops treatments for cardiometabolic and rare diseases. Govorestat, targeting galactosemia, is in late-stage trials with a potential FDA filing in 2025.

Aravive, Inc. (NASDAQ: ARAV)

• Description: Aravive, Inc. focuses on oncology with batiraxcept targeting the GAS6-AXL pathway. It's in Phase 2/3 trials for ovarian and pancreatic cancers, aiming to improve survival outcomes.

Arbutus Biopharma Corporation (NASDAQ: ABUS)

• Description: Arbutus Biopharma Corporation develops therapies for chronic hepatitis B. Imdusiran, an RNAi candidate, is in Phase 2 trials, targeting functional cures in combination therapies by 2025.

Arcus Biosciences, Inc. (NYSE: RCUS)

• Description: Arcus Biosciences, Inc. develops cancer immunotherapies with domvanalimab (anti-TIGIT) and etrumadenant in Phase 3 trials for lung and GI cancers, partnered with Gilead Sciences.

Ardelyx, Inc. (NASDAQ: ARDX)

• Description: Ardelyx, Inc. focuses on GI and cardiorenal therapies, marketing IBSRELA (tenapanor) for IBS-C and XPHOZAH for hyperphosphatemia, with expanded indications in development.

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)

• Description: Arena Pharmaceuticals, Inc., now under Pfizer, develops small molecule drugs like etrasimod for ulcerative colitis, advancing its immune-mediated disease pipeline in 2025.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)

• Description: Arrowhead Pharmaceuticals, Inc. develops RNAi therapeutics, with plozasiran for hypertriglyceridemia and zodasiran for dyslipidemia in late-stage trials, targeting approvals by 2025.

AstraZeneca PLC (NASDAQ: AZN)

• Description: AstraZeneca PLC is a global biopharma leader in oncology and respiratory diseases, marketing ENHERTU and IMFINZI, with a robust pipeline advancing in 2025.

Atara Biotherapeutics, Inc. (NASDAQ: ATRA)

• Description: Atara Biotherapeutics, Inc. develops allogeneic T-cell therapies, with tab-cel nearing U.S. approval for EBV+ PTLD following successful Phase 3 results in 2025.

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR)

• Description: Atea Pharmaceuticals, Inc. focuses on antiviral therapies for RNA viruses, with bemnifosbuvir in Phase 3 trials for hepatitis C, eyeing broader applications in 2025.

Athersys, Inc. (NASDAQ: ATHX)

• Description: Athersys, Inc. develops MultiStem cell therapy for neurological and inflammatory conditions, advancing trials for stroke and ARDS with partnerships in 2025.

Atossa Therapeutics, Inc. (NASDAQ: ATOS)

• Description: Atossa Therapeutics, Inc. focuses on breast cancer, with (Z)-endoxifen in Phase 2 trials for prevention and treatment, leveraging oral SERM technology in 2025.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH)

• Description: Aurinia Pharmaceuticals Inc. develops autoimmune therapies, marketing LUPKYNIS (voclosporin) for lupus nephritis, with research expanding into broader indications in 2025.

Autolus Therapeutics plc (NASDAQ: AUTL)

• Description: Autolus Therapeutics plc develops CAR-T therapies, with obecabtagene autoleucel (obe-cel) in pivotal trials for ALL, targeting potential approval in 2025.

Avadel Pharmaceuticals plc (NASDAQ: AVDL)

• Description: Avadel Pharmaceuticals plc focuses on sleep disorders, marketing LUMRYZ™ (sodium oxybate) for narcolepsy and expanding its sleep medicine portfolio in 2025.

AVEO Oncology (NASDAQ: AVEO)

• Description: AVEO Oncology, now part of LG Chem, markets FOTIVDA (tivozanib) for renal cell carcinoma, with its oncology portfolio growing under LG Chem in 2025.

Axsome Therapeutics, Inc. (NASDAQ: AXSM)

• Description: Axsome Therapeutics, Inc. develops CNS therapies, marketing AUVELITY for depression and SUNOSI for narcolepsy, with a pipeline targeting migraines and Alzheimer's.

Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC.TO)

• Description: Bausch Health Companies Inc. develops pharmaceuticals across gastroenterology and neurology, marketing XIFAXAN and advancing its specialty portfolio in 2025.

Baxter International Inc. (NYSE: BAX)

• Description: Baxter International Inc. provides medical products for acute and chronic care, including dialysis and IV solutions, with renal care innovations progressing in 2025.

Becton, Dickinson and Company (NYSE: BDX)

• Description: Becton, Dickinson and Company (BD) develops diagnostics and drug delivery systems, with the BD FACSDiscover™ S8 Cell Sorter advancing research capabilities in 2025.

BeiGene, Ltd. (NASDAQ: BGNE)

• Description: BeiGene, Ltd. develops cancer therapies, marketing BRUKINSA (zanubrutinib) for hematologic malignancies and advancing its oncology pipeline with late-stage trials.

Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM)

• Description: Bellicum Pharmaceuticals, Inc. develops cellular immunotherapies, with BPX-601 CAR-T therapy in trials for solid tumors, featuring a safety switch for enhanced control.

Bellerophon Therapeutics, Inc. (NASDAQ: BLPH)

• Description: Bellerophon Therapeutics, Inc. focuses on cardiopulmonary diseases, with INOpulse nitric oxide therapy in trials for pulmonary hypertension and fibrotic lung diseases.

BeyondSpring Inc. (NASDAQ: BYSI)

• Description: BeyondSpring Inc. develops cancer therapies, with plinabulin in late-stage trials for chemotherapy-induced neutropenia and NSCLC, targeting approvals in 2025.

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)

• Description: BioCryst Pharmaceuticals, Inc. develops oral drugs for rare diseases, marketing ORLADEYO for hereditary angioedema and advancing complement-mediated disease therapies.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI)

• Description: BioDelivery Sciences International, Inc., now part of Collegium Pharmaceutical, markets BELBUCA for chronic pain, enhancing drug delivery with its BEMA technology in 2025.

Biofrontera Inc. (NASDAQ: BFRI)

• Description: Biofrontera Inc. focuses on dermatology, marketing Ameluz for photodynamic therapy of actinic keratosis, with expanded U.S. adoption for skin cancer treatment in 2025.

Biohaven Ltd. (NYSE: BHVN)

• Description: Biohaven Ltd. develops neurological therapies, marketing NURTEC ODT for migraines and advancing candidates for OCD and spinocerebellar ataxia in late-stage trials.

BioLineRx Ltd. (NASDAQ: BLRX)

• Description: BioLineRx Ltd. develops oncology therapies, with APHEXDA (motixafortide) approved for stem cell mobilization in multiple myeloma and further trials ongoing.

BiomX Inc. (NYSE American: PHGE)

• Description: BiomX Inc. develops phage therapies for pathogenic bacteria, with BX004 in Phase 2 trials for cystic fibrosis-related lung infections, leveraging microbiome technology.

BioNTech SE (NASDAQ: BNTX)

• Description: BioNTech SE pioneers mRNA therapies, co-developing COMIRNATY with Pfizer and advancing cancer immunotherapies and infectious disease vaccines in 2025.

Bio-Path Holdings, Inc. (NASDAQ: BPTH)

• Description: Bio-Path Holdings, Inc. develops DNAbilize antisense RNAi therapies, with prexigebersen in Phase 2 trials for AML and potential expansion to solid tumors in 2025.

BioSig Technologies, Inc. (NASDAQ: BSGM)

• Description: BioSig Technologies, Inc. develops bioelectronic technologies, with PURE EP™ enhancing cardiac electrophysiology procedures, gaining clinical traction in 2025.

BioXcel Therapeutics, Inc. (NASDAQ: BTAI)

• Description: BioXcel Therapeutics, Inc. uses AI for neuroscience and oncology therapies, marketing IGALMI™ for agitation and advancing BXCL701 for pancreatic cancer.

Black Diamond Therapeutics, Inc. (NASDAQ: BDTX)

• Description: Black Diamond Therapeutics, Inc. develops precision oncology therapies, with BDTX-1535 in Phase 2 trials for EGFR-mutant lung cancer and glioblastoma in 2025.

Blueprint Medicines Corporation (NASDAQ: BPMC)

• Description: Blueprint Medicines Corporation develops precision therapies, marketing AYVAKIT for GIST and advancing zanzalintinib for lung cancer and mastocytosis.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI)

• Description: BrainStorm Cell Therapeutics Inc. develops autologous stem cell therapies, with NurOwn in late-stage trials for ALS and potential expansion to other CNS disorders.

BridgeBio Pharma, Inc. (NASDAQ: BBIO)

• Description: BridgeBio Pharma, Inc. targets genetic diseases, with acoramidis in late-stage trials for transthyretin amyloid cardiomyopathy and a broad pipeline for rare disorders.

Bristol Myers Squibb (NYSE: BMY)

• Description: Bristol Myers Squibb is a global biopharma leader, marketing OPDIVO and REBLOZYL, with a robust pipeline in oncology and immunology advancing in 2025.

C4 Therapeutics, Inc. (NASDAQ: CCCC)

• Description: C4 Therapeutics, Inc. develops protein degradation therapies, with CFT7455 and CFT1946 in Phase 1/2 trials for multiple myeloma and solid tumors.

Caladrius Biosciences, Inc. (NASDAQ: CLBS)

• Description: Caladrius Biosciences, Inc., now Lisata Therapeutics, develops cellular therapies, with LSTA1 in Phase 1b/2 trials enhancing tumor penetration for pancreatic cancer.

Calithera Biosciences, Inc. (NASDAQ: CALA)

• Description: Calithera Biosciences, Inc. develops small molecule therapies, with CB-839 (telaglenastat) in trials for renal cell carcinoma and strategic partnerships in 2025.

Cardiff Oncology, Inc. (NASDAQ: CRDF)

• Description: Cardiff Oncology, Inc. develops onvansertib, a PLK1 inhibitor, for KRAS-mutated cancers, in Phase 2 trials for colorectal and pancreatic cancers.

Cardinal Health, Inc. (NYSE: CAH)

• Description: Cardinal Health, Inc. supports biotech with drug distribution and medical products, enhancing healthcare delivery with logistics and specialty solutions in 2025.

Cardiol Therapeutics Inc. (NASDAQ: CRDL)

• Description: Cardiol Therapeutics Inc. develops anti-inflammatory therapies, with CardiolRx™ in Phase 2/3 trials for myocarditis and heart failure in 2025.

CareDx, Inc. (NASDAQ: CDNA)

• Description: CareDx, Inc. provides diagnostic solutions for transplant patients, with AlloSure and AlloMap monitoring organ rejection, expanding applications in 2025.

Caribou Biosciences, Inc. (NASDAQ: CRBU)

• Description: Caribou Biosciences, Inc. develops CRISPR-edited CAR-T therapies, with CB-010 in Phase 1 trials for B-cell malignancies showing early promise.

Cassava Sciences, Inc. (NASDAQ: SAVA)

• Description: Cassava Sciences, Inc. targets Alzheimer's with simufilam in Phase 3 trials, aiming to address amyloid-beta pathology with potential 2025 outcomes.

Castle Biosciences, Inc. (NASDAQ: CSTL)

• Description: Castle Biosciences, Inc. develops diagnostic tests for skin cancers, with DecisionDx guiding treatment decisions and expanding into new indications in 2025.

Celldex Therapeutics, Inc. (NASDAQ: CLDX)

• Description: Celldex Therapeutics, Inc. develops immunotherapies, with barzolvolimab in Phase 2 trials for mast cell disorders and potential broader applications.

Cellectar Biosciences, Inc. (NASDAQ: CLRB)

• Description: Cellectar Biosciences, Inc. develops phospholipid drug conjugates, with iopofosine I 131 in pivotal trials for Waldenström's macroglobulinemia, targeting approval in 2025.

Celsius Therapeutics, Inc. (NASDAQ: CLSH)

• Description: Celsius Therapeutics, Inc. uses single-cell genomics for precision therapies in autoimmune diseases and cancer, advancing preclinical programs toward trials in 2025.

Centogene N.V. (NASDAQ: CNTG)

• Description: Centogene N.V. provides genetic diagnostics for rare diseases, with its CENTOGENE Biodatabank supporting drug development through partnerships in 2025.

Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)

• Description: Cerevel Therapeutics Holdings, Inc., now part of AbbVie, develops neuroscience therapies, with emraclidine in Phase 2 trials for schizophrenia under AbbVie's oversight.

Cerus Corporation (NASDAQ: CERS)

• Description: Cerus Corporation develops the INTERCEPT Blood System to enhance blood safety, expanding its transfusion medicine applications globally in 2025.

ChemoCentryx, Inc. (NASDAQ: CCXI)

• Description: ChemoCentryx, Inc., now part of Amgen, markets TAVNEOS for ANCA-associated vasculitis, bolstering Amgen's inflammatory disease portfolio in 2025.

Chimerix, Inc. (NASDAQ: CMRX)

• Description: Chimerix, Inc., acquired by Jazz Pharmaceuticals, develops antiviral therapies, with dordaviprone in trials for H3 K27M-mutant glioma, nearing FDA review in 2025.

Clene Inc. (NASDAQ: CLNN)

• Description: Clene Inc. develops nanotherapeutics, with CNM-Au8 in Phase 3 trials for ALS and MS, aiming to improve cellular energy and neurological function.

Clover Health Investments, Corp. (NASDAQ: CLOV)

• Description: Clover Health Investments, Corp. leverages AI-driven platforms for Medicare Advantage healthcare, enhancing patient outcomes with medical tech in 2025.

Co-Diagnostics, Inc. (NASDAQ: CODX)

• Description: Co-Diagnostics, Inc. develops molecular diagnostics, with its Co-Dx PCR platform expanding at-home testing for infectious diseases globally in 2025.

Cognition Therapeutics, Inc. (NASDAQ: CGTX)

• Description: Cognition Therapeutics, Inc. develops small molecule therapies for neurodegenerative diseases, with CT1812 in Phase 2 trials for Alzheimer's targeting synaptic protection.

Compugen Ltd. (NASDAQ: CGEN)

• Description: Compugen Ltd. uses computational biology for cancer immunotherapies, with COM701 in Phase 1/2 trials for solid tumors, advancing with partnerships in 2025.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)

• Description: Concert Pharmaceuticals, Inc., now part of Sun Pharma, markets CTP-543 (deuruxolitinib) for alopecia areata, enhancing its portfolio with deuterium chemistry in 2025.

Corcept Therapeutics Incorporated (NASDAQ: CORT)

• Description: Corcept Therapeutics Incorporated develops cortisol modulators, marketing KORLYM for Cushing's syndrome and advancing relacorilant for adrenal cancer in Phase 3 trials.

Cortexyme, Inc. (NASDAQ: CRTX)

• Description: Cortexyme, Inc., now Quince Therapeutics, targets rare diseases with NOV004 in preclinical development for osteogenesis imperfecta, shifting focus in 2025.

Cue Biopharma, Inc. (NASDAQ: CUE)

• Description: Cue Biopharma, Inc. develops Immuno-STAT™ biologics for cancer and autoimmune diseases, with CUE-101 in Phase 1 trials for head and neck cancer.

CureVac N.V. (NASDAQ: CVAC)

• Description: CureVac N.V. develops mRNA-based vaccines and therapeutics, with CVnCoV in late-stage trials for COVID-19 and oncology applications expanding in 2025.

Cymabay Therapeutics, Inc. (NASDAQ: CBAY)

• Description: Cymabay Therapeutics, Inc., now part of Gilead, markets seladelpar for primary biliary cholangitis, enhancing Gilead's liver disease offerings in 2025.

Cytokinetics, Incorporated (NASDAQ: CYTK)

• Description: Cytokinetics, Incorporated develops muscle-targeted therapies, with aficamten in Phase 3 for hypertrophic cardiomyopathy, nearing potential approval in 2025.

CytomX Therapeutics, Inc. (NASDAQ: CXTM)

• Description: CytomX Therapeutics, Inc. develops Probody therapeutics, with CX-904 in Phase 1/2 trials with Amgen for solid tumors, targeting precision oncology.

Daré Bioscience, Inc. (NASDAQ: DARE)

• Description: Daré Bioscience, Inc. focuses on women's health, with Ovaprene and Sildenafil Cream in trials for contraception and female sexual arousal disorder, respectively.

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN)

• Description: Day One Biopharmaceuticals, Inc. develops pediatric cancer therapies, with tovorafenib in pivotal trials for relapsed low-grade glioma, targeting approval in 2025.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)

• Description: Deciphera Pharmaceuticals, Inc., now part of Ono Pharmaceutical, markets QINLOCK for GIST, with its kinase inhibitor platform expanding under Ono in 2025.

Denali Therapeutics Inc. (NASDAQ: DNLI)

• Description: Denali Therapeutics Inc. develops therapies for neurodegenerative diseases, with DNL310 in Phase 2/3 trials for Hunter syndrome and candidates for Alzheimer's advancing.

DermTech, Inc. (NASDAQ: DMTK)

• Description: DermTech, Inc. offers non-invasive genomic tests for skin cancer, with its DermTech Melanoma Test expanding early detection in dermatology practices in 2025.

Durect Corporation (NASDAQ: DRRX)

• Description: Durect Corporation develops therapies for chronic pain and liver diseases, with larsucosterol in Phase 3 trials for alcohol-associated hepatitis, targeting breakthrough status in 2025.

Dyadic International, Inc. (NASDAQ: DYAI)

• Description: Dyadic International, Inc. uses its C1 fungal platform for protein production, advancing vaccine and therapeutic candidates like DYAI-100 in partnerships for biomanufacturing.

Dynavax Technologies Corporation (NASDAQ: DVAX)

• Description: Dynavax Technologies Corporation develops vaccines with CpG 1018 adjuvant, marketing HEPLISAV-B and expanding oncology applications in 2025.

Edesa Biotech, Inc. (NASDAQ: EDSA)

• Description: Edesa Biotech, Inc. develops therapies for inflammatory diseases, with EB05 in Phase 3 trials for ARDS, aiming to address critical care needs in 2025.

Edgewise Therapeutics, Inc. (NASDAQ: EWTX)

• Description: Edgewise Therapeutics, Inc. targets muscle diseases, with sevasemten in Phase 3 trials for Becker muscular dystrophy and preclinical work for Duchenne in 2025.

Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR)

• Description: Eiger BioPharmaceuticals, Inc. develops therapies for rare metabolic diseases, marketing Zokinvy for progeria and advancing trials for hepatitis delta virus.

Eldorado Gold Corporation (NYSE: EGO) (TSX: ELD.TO)

• Description: Eldorado Gold Corporation, a mining company, indirectly supports biotech through investments, funding medical tech innovations with its resources in 2025.

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN)

• Description: Eledon Pharmaceuticals, Inc. develops immune-modulating therapies, with tegoprubart in Phase 2 trials for transplant rejection and ALS, improving patient outcomes.

Elevation Oncology, Inc. (NASDAQ: ELEV)

• Description: Elevation Oncology, Inc. focuses on precision oncology, with seribantumab in Phase 2 trials for NRG1 fusion-positive tumors and new genomic targets in development.

Eli Lilly and Company (NYSE: LLY)

• Description: Eli Lilly and Company leads in diabetes and oncology, marketing MOUNJARO and advancing Alzheimer's therapies like donanemab with significant 2025 milestones.

Emergent BioSolutions Inc. (NYSE: EBS)

• Description: Emergent BioSolutions Inc. provides public health solutions, marketing NARCAN and vaccines like ACAM2000, with biodefense contracts growing in 2025.

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA)

• Description: Enanta Pharmaceuticals, Inc. develops small molecule drugs for viral infections, with candidates targeting RSV and NASH in clinical trials for 2025.

Endo International plc (NASDAQ: ENDP)

• Description: Endo International plc develops specialty pharmaceuticals, marketing XIAFLEX for Dupuytren's contracture and advancing pain management therapies in 2025.

Enlivex Therapeutics Ltd. (NASDAQ: ENLV)

• Description: Enlivex Therapeutics Ltd. develops Allocetra™, an allogeneic cell therapy for sepsis and osteoarthritis, with Phase 2 trials progressing in 2025.

Entrada Therapeutics, Inc. (NASDAQ: TRDA)

• Description: Entrada Therapeutics, Inc. develops intracellular therapeutics, with ENTR-601-44 in Phase 1 trials for Duchenne muscular dystrophy using its EEV™ platform.

Esperion Therapeutics, Inc. (NASDAQ: ESPR)

• Description: Esperion Therapeutics, Inc. focuses on lipid management, marketing NEXLETOL and NEXLIZET for cholesterol, with expanded indications in development for 2025.

Eton Pharmaceuticals, Inc. (NASDAQ: ETON)

• Description: Eton Pharmaceuticals, Inc. commercializes treatments for rare diseases, marketing ALKINDI SPRINKLE and advancing pediatric therapies in its pipeline.

Evaxion Biotech A/S (NASDAQ: EVAX)

• Description: Evaxion Biotech A/S uses AI for personalized cancer vaccines, with EVX-01 in Phase 2 trials for melanoma, leveraging its PIONEER™ platform in 2025.

Evelo Biosciences, Inc. (NASDAQ: EVLO)

• Description: Evelo Biosciences, Inc. develops oral microbiome therapies, with EDP1815 in Phase 2 trials for psoriasis and atopic dermatitis, targeting inflammation.

Exact Sciences Corporation (NASDAQ: EXAS)

• Description: Exact Sciences Corporation provides cancer diagnostics, marketing Cologuard and expanding Oncotype DX for precision oncology in 2025.

Exelixis, Inc. (NASDAQ: EXEL)

• Description: Exelixis, Inc. develops oncology therapies, marketing CABOMETYX for RCC and advancing zanzalintinib in late-stage trials for multiple cancers.

Fate Therapeutics, Inc. (NASDAQ: FATE)

• Description: Fate Therapeutics, Inc. develops iPSC-derived cell therapies, with FT819 and FT522 in Phase 1 trials for B-cell malignancies, showing early efficacy in 2025.

FibroGen, Inc. (NASDAQ: FGEN)

• Description: FibroGen, Inc. develops therapies for anemia and fibrosis, marketing roxadustat for CKD anemia and advancing pamrevlumab for pancreatic cancer and IPF.

First Wave BioPharma, Inc. (NASDAQ: FWBI)

• Description: First Wave BioPharma, Inc. focuses on GI diseases, with adrulipase in Phase 2 trials for exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis.

G1 Therapeutics, Inc. (NASDAQ: GTHX)

• Description: G1 Therapeutics, Inc. develops cancer therapies, marketing COSELA (trilaciclib) to reduce chemotherapy-induced myelosuppression, with trials expanding its use in 2025.

Galapagos NV (NASDAQ: GLPG)

• Description: Galapagos NV focuses on novel therapeutics, advancing its CAR-T and small molecule pipeline for oncology and inflammatory diseases, with clinical progress in 2025.

Genocea Biosciences, Inc. (NASDAQ: GNCA)

• Description: Genocea Biosciences, Inc. develops cancer vaccines, with GEN-011, a neoantigen-targeted T-cell therapy, in Phase 1/2 trials for solid tumors, aiming for personalized immunotherapy.

Geron Corporation (NASDAQ: GERN)

• Description: Geron Corporation develops imetelstat, a telomerase inhibitor, in Phase 3 trials for myelodysplastic syndromes and myelofibrosis, targeting potential approval in 2025.

Gilead Sciences, Inc. (NASDAQ: GILD)

• Description: Gilead Sciences, Inc. is a global biopharma leader, marketing BIKTARVY for HIV and TRODELVY for cancer, with a broad pipeline advancing in virology and oncology.

Glaukos Corporation (NYSE: GKOS)

• Description: Glaukos Corporation develops ophthalmic therapies, marketing iStent for glaucoma and expanding its iDose platform for sustained drug delivery in 2025.

Global Blood Therapeutics, Inc. (NASDAQ: GBT)

• Description: Global Blood Therapeutics, Inc., now part of Pfizer, markets OXBRYTA (voxelotor) for sickle cell disease, with Pfizer enhancing its rare disease portfolio in 2025.

GlycoMimetics, Inc. (NASDAQ: GMMI)

• Description: GlycoMimetics, Inc. develops glycobiology-based therapies, with uproleselan in Phase 3 trials for AML, aiming to improve chemotherapy outcomes in 2025.

Gossamer Bio, Inc. (NASDAQ: GOSS)

• Description: Gossamer Bio, Inc. focuses on immunology and respiratory diseases, with seralutinib in Phase 3 trials for pulmonary arterial hypertension, targeting symptom relief.

Gritstone bio, Inc. (NASDAQ: GRTS)

• Description: Gritstone bio, Inc. develops personalized cancer vaccines, with GRANITE in Phase 2/3 trials for colorectal cancer, leveraging neoantigen prediction technology.

Guardant Health, Inc. (NASDAQ: GH)

• Description: Guardant Health, Inc. provides liquid biopsy tests, marketing Guardant360 for cancer profiling and advancing Shield™ for colorectal cancer screening in 2025.

Halozyme Therapeutics, Inc. (NASDAQ: HALO)

• Description: Halozyme Therapeutics, Inc. develops ENHANZE drug delivery technology, enhancing subcutaneous administration for biotech partners, with expanded applications in 2025.

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY)

• Description: Harmony Biosciences Holdings, Inc. markets WAKIX (pitolisant) for narcolepsy, with trials exploring new indications like Prader-Willi syndrome in 2025.

Heron Therapeutics, Inc. (NASDAQ: HRTX)

• Description: Heron Therapeutics, Inc. develops therapies for pain and nausea, marketing ZYNRELEF for postoperative pain and expanding its supportive care portfolio.

Heska Corporation (NASDAQ: HSKA)

• Description: Heska Corporation, now part of Mars, provides veterinary diagnostics and imaging, enhancing animal healthcare with its Element™ platforms in 2025.

Hologic, Inc. (NASDAQ: HOLX)

• Description: Hologic, Inc. develops diagnostics and medical imaging, marketing Panther for molecular testing and advancing breast cancer detection technologies in 2025.

HOOKIPA Pharma Inc. (NASDAQ: HOOK)

• Description: HOOKIPA Pharma Inc. develops arenaviral immunotherapies, with HB-200 in Phase 2 trials for HPV16+ head and neck cancers, aiming to boost immune responses.

Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)

• Description: Horizon Therapeutics, now part of Amgen, markets TEPEZZA for thyroid eye disease and UPLIZNA for neuromyelitis optica, enhancing Amgen's rare disease offerings in 2025.

Humanigen, Inc. (NASDAQ: HGEN)

• Description: Humanigen, Inc. develops lenzilumab, a monoclonal antibody for cytokine storm, with trials ongoing for CAR-T therapy side effects and chronic myelomonocytic leukemia in 2025.

HUTCHMED (China) Limited (NASDAQ: HCM)

• Description: HUTCHMED (China) Limited develops oncology and immunology therapies, marketing ELUNATE and SULANDA in China, with global trials expanding in 2025.

I-Mab (NASDAQ: IMAB)

• Description: I-Mab develops biologics for immuno-oncology, with lemzoparlimab in Phase 2 trials for solid tumors and autoimmune diseases, advancing its global pipeline.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA)

• Description: IDEAYA Biosciences, Inc. develops precision oncology therapies, with IDE397 in Phase 2 trials for MTAP-deletion cancers and darovasertib for uveal melanoma.

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA)

• Description: Idera Pharmaceuticals, Inc. focuses on toll-like receptor antagonists, with tilsotolimod in trials for melanoma and head and neck cancers, partnered with Bristol Myers Squibb.

Illumina, Inc. (NASDAQ: ILMN)

• Description: Illumina, Inc. provides genomic sequencing solutions, with NovaSeq™ and NextSeq™ platforms driving precision medicine and diagnostics in biotech research in 2025.

ImmunityBio, Inc. (NASDAQ: IBRX)

• Description: ImmunityBio, Inc. develops immunotherapies, with Anktiva (N-803) in Phase 3 trials for bladder cancer, aiming for FDA approval in 2025.

Immunocore Holdings plc (NASDAQ: IMCR)

• Description: Immunocore Holdings plc develops TCR therapies, marketing KIMMTRAK (tebentafusp) for uveal melanoma and advancing candidates for other cancers.

ImmunoGen, Inc. (NASDAQ: IMGN)

• Description: ImmunoGen, Inc., now part of AbbVie, markets ELAHERE (mirvetuximab soravtansine) for ovarian cancer, with AbbVie expanding its ADC platform in 2025.

Immunovant, Inc. (NASDAQ: IMVT)

• Description: Immunovant, Inc. develops therapies for autoimmune diseases, with batoclimab and IMVT-1402 in Phase 2/3 trials for myasthenia gravis and thyroid eye disease.

Incyte Corporation (NASDAQ: INCY)

• Description: Incyte Corporation develops oncology and dermatology therapies, marketing JAKAFI (ruxolitinib) and advancing its JAK inhibitor pipeline in 2025.

Inhibrx, Inc. (NASDAQ: INBX)

• Description: Inhibrx, Inc. develops biologics, with INBRX-101 in Phase 2 trials for alpha-1 antitrypsin deficiency, targeting protein replacement therapy advancements.

InMed Pharmaceuticals Inc. (NASDAQ: INM)

• Description: InMed Pharmaceuticals Inc. develops cannabinoid-based therapies, with INM-755 in trials for epidermolysis bullosa and INM-088 for glaucoma, progressing in 2025.

Inmune Bio, Inc. (NASDAQ: INMB)

• Description: Inmune Bio, Inc. develops immunotherapies, with XPro™ in Phase 2 trials for Alzheimer's and NK cell therapies for cancer advancing in 2025.

Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT)

• Description: Innovate Biopharmaceuticals, Inc., now 9 Meters Biopharma, develops therapies for GI disorders, with larazotide in trials for celiac disease and short bowel syndrome.

Inovio Pharmaceuticals, Inc. (NASDAQ: INO)

• Description: Inovio Pharmaceuticals, Inc. develops DNA medicines, with INO-4800 in trials for COVID-19 and INO-3107 for HPV-related diseases, targeting approvals in 2025.

Inozyme Pharma, Inc. (NASDAQ: INZY)

• Description: Inozyme Pharma, Inc. develops therapies for rare mineralization disorders, with INZ-701 in Phase 1/2 trials for ENPP1 deficiency and ABCC6 deficiency.

Inspire Medical Systems, Inc. (NYSE: INSP)

• Description: Inspire Medical Systems, Inc. markets the Inspire therapy for obstructive sleep apnea, expanding its neurostimulation device adoption in sleep medicine in 2025.

Instil Bio, Inc. (NASDAQ: TIL)

• Description: Instil Bio, Inc. develops TIL therapies for solid tumors, with ITIL-306 in Phase 1 trials for lung and ovarian cancers, leveraging tumor-infiltrating lymphocytes.

Intellia Therapeutics, Inc. (NASDAQ: NTLA)

• Description: Intellia Therapeutics, Inc. develops CRISPR-based therapies, with NTLA-2001 in Phase 1/2 trials for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema.

Intuitive Surgical, Inc. (NASDAQ: ISRG)

• Description: Intuitive Surgical, Inc. develops robotic surgical systems, with the da Vinci system leading minimally invasive surgery, expanding applications in 2025.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)

• Description: Ionis Pharmaceuticals, Inc. develops antisense therapies, marketing SPINRAZA for SMA and advancing eplontersen for ATTR amyloidosis in late-stage trials.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)

• Description: Iovance Biotherapeutics, Inc. develops TIL therapies, with lifileucel approved for advanced melanoma in 2024 and trials expanding to other cancers in 2025.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)

• Description: Ironwood Pharmaceuticals, Inc. markets LINZESS (linaclotide) for IBS-C and chronic constipation, with a pipeline targeting GI and metabolic disorders.

IsoRay, Inc. (NYSE American: ISR)

• Description: IsoRay, Inc., now Viewpoint Molecular Targeting, develops Cesium-131 brachytherapy for cancer, with expanded applications in prostate and brain tumors in 2025.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ)

• Description: Jazz Pharmaceuticals plc markets XYREM for narcolepsy and EPIDIOLEX for epilepsy, with a pipeline advancing in oncology and neuroscience in 2025.

Karyopharm Therapeutics Inc. (NASDAQ: KPTI)

• Description: Karyopharm Therapeutics Inc. markets XPOVIO (selinexor) for multiple myeloma, with trials expanding its use in endometrial cancer and myelofibrosis.

Keros Therapeutics, Inc. (NASDAQ: KROS)

• Description: Keros Therapeutics, Inc. develops therapies for hematologic and musculoskeletal disorders, with KER-050 in Phase 2 trials for myelodysplastic syndromes.

Kezar Life Sciences, Inc. (NASDAQ: KZR)

• Description: Kezar Life Sciences, Inc. develops immunoproteasome inhibitors, with zetomipzomib in Phase 2 trials for lupus nephritis and autoimmune hepatitis in 2025.

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA)

• Description: Kiniksa Pharmaceuticals, Ltd. markets ARCALYST (rilonacept) for recurrent pericarditis, with vixarelimab and abiprubart advancing for inflammatory diseases in trials.

Kinnate Biopharma Inc. (NASDAQ: KNTE)

• Description: Kinnate Biopharma Inc. develops kinase inhibitors, with exarafenib in Phase 1 trials for BRAF-mutated cancers, targeting precision oncology advancements.

Kodiak Sciences Inc. (NASDAQ: KOD)

• Description: Kodiak Sciences Inc. develops retinal therapies, with tarcocimab in Phase 3 trials for diabetic macular edema and wet AMD, leveraging its ABC Platform™.

Krystal Biotech, Inc. (NASDAQ: KRYS)

• Description: Krystal Biotech, Inc. markets VYJUVEK (beremagene geperpavec) for dystrophic epidermolysis bullosa, with a gene therapy pipeline expanding in 2025.

Kura Oncology, Inc. (NASDAQ: KURA)

• Description: Kura Oncology, Inc. develops precision oncology therapies, with ziftomenib in Phase 2 trials for NPM1-mutant AML, targeting regulatory milestones in 2025.

Kyowa Kirin Co., Ltd. (Tokyo: 4151.T)

• Description: Kyowa Kirin Co., Ltd. develops biologics, marketing POTELIGEO for T-cell lymphomas and advancing istradefylline for Parkinson's in global markets in 2025.

Legend Biotech Corporation (NASDAQ: LEGN)

• Description: Legend Biotech Corporation markets CARVYKTI (ciltacabtagene autoleucel) for multiple myeloma, with trials expanding its CAR-T platform in 2025.

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX)

• Description: Lexicon Pharmaceuticals, Inc. develops small molecule drugs, with sotagliflozin in trials for heart failure and type 1 diabetes, targeting approvals in 2025.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)

• Description: Ligand Pharmaceuticals Incorporated develops Captisol-enabled drugs, supporting biotech partners with its technology platform and advancing its internal pipeline.

Limbach Holdings, Inc. (NASDAQ: LMB)

• Description: Limbach Holdings, Inc., a building systems company, indirectly supports biotech through facility solutions, enhancing lab and manufacturing environments in 2025.

Lineage Cell Therapeutics, Inc. (NYSE American: LCTX)

• Description: Lineage Cell Therapeutics, Inc. develops cell therapies, with OpRegen in trials for dry AMD and OPC1 for spinal cord injury advancing in 2025.

Lipocine Inc. (NASDAQ: LPCN)

• Description: Lipocine Inc. develops oral delivery therapies, with TLANDO (testosterone undecanoate) marketed for hypogonadism and LPCN 1144 in trials for NASH.

Liquidia Corporation (NASDAQ: LQDA)

• Description: Liquidia Corporation develops inhaled therapies using PRINT technology, with YUTREPIA™ (treprostinil) in trials for pulmonary arterial hypertension, targeting approval in 2025.

Luminary Therapeutics, Inc. (OTC: LMTX)

• Description: Luminary Therapeutics, Inc. develops cell therapies, with its BAFF CAR-T in preclinical stages for mantle cell lymphoma, leveraging multi-targeting approaches.

Lyra Therapeutics, Inc. (NASDAQ: LYRA)

• Description: Lyra Therapeutics, Inc. develops nasal therapies, with LYR-210 in Phase 3 trials for chronic rhinosinusitis, using its XTreo™ platform for sustained delivery.

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)

• Description: Madrigal Pharmaceuticals, Inc. develops resmetirom for NASH, with Phase 3 trials completed and potential FDA approval pending in 2025 for liver disease treatment.

MannKind Corporation (NASDAQ: MNKD)

• Description: MannKind Corporation markets AFREZZA (inhaled insulin) for diabetes, with its Technosphere platform expanding into pulmonary delivery for other therapies in 2025.

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS)

• Description: Marinus Pharmaceuticals, Inc. markets ZTALMY (ganaxolone) for CDKL5 deficiency disorder, with trials expanding its use in epilepsy and tuberous sclerosis complex.

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB)

• Description: Matinas BioPharma Holdings, Inc. develops lipid nanocrystal delivery, with MAT2203 (oral amphotericin B) in trials for fungal infections and a pipeline for chronic diseases.

Medpace Holdings, Inc. (NASDAQ: MEDP)

• Description: Medpace Holdings, Inc. provides clinical research services, supporting biotech drug development with full-service CRO capabilities in 2025.

Merck & Co., Inc. (NYSE: MRK)

• Description: Merck & Co., Inc. is a global biopharma leader, marketing KEYTRUDA (pembrolizumab) for cancer and advancing its oncology and vaccine pipeline in 2025.

Mersana Therapeutics, Inc. (NASDAQ: MRSN)

• Description: Mersana Therapeutics, Inc. develops ADC therapies, with upifitamab rilsodotin in Phase 1 trials for ovarian cancer, leveraging its Dolaflexin platform.

MiMedx Group, Inc. (NASDAQ: MDXG)

• Description: MiMedx Group, Inc. markets placental-based allografts like EPIFIX for wound care and osteoarthritis, with expanded applications in regenerative medicine in 2025.

Mirati Therapeutics, Inc. (NASDAQ: MRTX)

• Description: Mirati Therapeutics, Inc., now part of Bristol Myers Squibb, markets KRAZATI (adagrasib) for KRAS G12C-mutated cancers, enhancing BMS's oncology portfolio in 2025.

Moderna, Inc. (NASDAQ: MRNA)

• Description: Moderna, Inc. pioneers mRNA therapies, marketing Spikevax for COVID-19 and advancing cancer and rare disease vaccines in late-stage trials in 2025.

Molecular Templates, Inc. (NASDAQ: MTEM)

• Description: Molecular Templates, Inc. develops engineered toxin bodies, with MT-6402 in Phase 1 trials for PD-L1-positive tumors, targeting immune checkpoint modulation.

Morphic Holding, Inc. (NASDAQ: MORF)

• Description: Morphic Holding, Inc. develops oral integrin therapies, with MORF-057 in Phase 2 trials for ulcerative colitis and Crohn's disease, advancing in 2025.

Myovant Sciences Ltd. (NYSE: MYOV)

• Description: Myovant Sciences Ltd., now part of Sumitomo Pharma, markets ORGOVYX (relugolix) for prostate cancer and MYFEMBREE for women's health, expanding under Sumitomo in 2025.

NantKwest, Inc. (NASDAQ: NK)

• Description: NantKwest, Inc., now ImmunityBio, markets Anktiva for bladder cancer, with its NK cell platform advancing in trials for other indications in 2025.

Natera, Inc. (NASDAQ: NTRA)

• Description: Natera, Inc. provides cfDNA testing, marketing Signatera™ for cancer recurrence monitoring and Prospera™ for transplant rejection, with expanded oncology applications in 2025.

Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)

• Description: Neoleukin Therapeutics, Inc. develops de novo protein therapeutics, with NL-201 in preclinical stages for cancer and inflammation, leveraging computational design.

NervGen Pharma Corp. (TSXV: NGEN)

• Description: NervGen Pharma Corp. develops NVG-291 for nerve regeneration, in Phase 1/2 trials for spinal cord injury and multiple sclerosis, targeting neural repair in 2025.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX)

• Description: Neurocrine Biosciences, Inc. markets INGREZZA (valbenazine) for tardive dyskinesia, with a pipeline advancing for epilepsy and Parkinson's in 2025.

NGM Biopharmaceuticals, Inc. (NASDAQ: NGM)

• Description: NGM Biopharmaceuticals, Inc. develops biologics for metabolic and oncology indications, with NGM707 in Phase 2 trials for solid tumors, partnered with Merck.

Nkarta, Inc. (NASDAQ: NKTX)

• Description: Nkarta, Inc. develops NK cell therapies, with NKX101 and NKX019 in Phase 1 trials for AML and lymphoma, leveraging engineered natural killer cells.

Nuvation Bio Inc. (NYSE: NUVB)

• Description: Nuvation Bio Inc. develops oncology therapies, with NUV-868 in Phase 1/2 trials for solid tumors, targeting BET proteins for cancer treatment.

Ocular Therapeutix, Inc. (NASDAQ: OCUL)

• Description: Ocular Therapeutix, Inc. markets DEXTENZA for ocular inflammation and develops OTX-TKI for wet AMD, with Phase 2 trials advancing in 2025.

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA)

• Description: Olema Pharmaceuticals, Inc. develops therapies for women's cancers, with OP-1250 in Phase 2 trials for ER+ breast cancer, targeting complete estrogen receptor antagonism.

OncoCyte Corporation (NASDAQ: OCX)

• Description: OncoCyte Corporation develops diagnostic tests, with DetermaRx™ for lung cancer treatment stratification and VitaGraft™ for transplant monitoring expanding in 2025.

Oncology Pharma Inc. (OTC: ONPH)

• Description: Oncology Pharma Inc. develops cancer therapies, with preclinical candidates leveraging nanotechnology for targeted drug delivery, progressing toward trials in 2025.

OncoSec Medical Incorporated (NASDAQ: ONCS)

• Description: OncoSec Medical Incorporated develops intratumoral immunotherapies, with TAVO™ (tavokinogene telseplasmid) in trials for melanoma and triple-negative breast cancer.

OPKO Health, Inc. (NASDAQ: OPK)

• Description: OPKO Health, Inc. markets RAYALDEE for secondary hyperparathyroidism and develops diagnostics and biologics, with a pipeline targeting growth hormone deficiencies.

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP)

• Description: Oramed Pharmaceuticals Inc. develops oral protein delivery, with ORMD-0801 in Phase 3 trials for type 2 diabetes, targeting insulin delivery innovation in 2025.

Organogenesis Holdings Inc. (NASDAQ: ORGO)

• Description: Organogenesis Holdings Inc. markets regenerative medicine products like Apligraf and PuraPly for wound care, expanding its advanced wound healing portfolio.

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC)

• Description: Oric Pharmaceuticals, Inc. develops therapies for resistant cancers, with ORIC-944 in Phase 1 trials for prostate cancer and glioblastoma, targeting PRC2 inhibition.

Otonomy, Inc. (NASDAQ: OTIC)

• Description: Otonomy, Inc. develops ear therapies, with OTO-313 in trials for tinnitus and OTO-413 for hearing loss, advancing its neurotology pipeline in 2025.

Oyster Point Pharma, Inc. (NASDAQ: OYST)

• Description: Oyster Point Pharma, Inc., now part of Viatris, markets TYRVAYA (varenicline nasal spray) for dry eye disease, enhancing Viatris's eye care offerings in 2025.

Palisade Bio, Inc. (NASDAQ: PALI)

• Description: Palisade Bio, Inc. develops GI therapies, with LB1148 in Phase 2 trials to reduce post-surgical adhesions and accelerate GI recovery in 2025.

PAVmed Inc. (NASDAQ: PAVM)

• Description: PAVmed Inc. develops medical devices, with EsoGuard and EsoCheck for esophageal cancer detection and CarpX for carpal tunnel syndrome advancing in 2025.

PDS Biotechnology Corporation (NASDAQ: PDSB)

• Description: PDS Biotechnology Corporation develops Versamune-based immunotherapies, with PDS0101 in Phase 2 trials for HPV-associated cancers, targeting immune activation.

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM)

• Description: Peregrine Pharmaceuticals, Inc., now Avid Bioservices, provides CDMO services for biotech, supporting drug development with manufacturing expertise in 2025.

Pfizer Inc. (NYSE: PFE)

• Description: Pfizer Inc. is a global biopharma leader, marketing PREVNAR vaccines and PAXLOVID for COVID-19, with a pipeline advancing in oncology and rare diseases.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB)

• Description: PharmaCyte Biotech, Inc. develops cellular encapsulation therapies, with its lead candidate in trials for pancreatic cancer, leveraging its Cell-in-a-Box technology.

PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS)

• Description: PhaseBio Pharmaceuticals, Inc. develops biopolymer-based therapies, with bentracimab in trials to reverse antiplatelet effects, advancing with SFJ Pharmaceuticals in 2025.

Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS)

• Description: Pieris Pharmaceuticals, Inc. develops Anticalin proteins, with cinrebafusp alfa in trials for HER2-positive cancers, partnered with Seagen and others.

Pliant Therapeutics, Inc. (NASDAQ: PLRX)

• Description: Pliant Therapeutics, Inc. develops therapies for fibrosis, with bexotegrast in Phase 2b trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

Pluristem Therapeutics Inc. (NASDAQ: PSTI)

• Description: Pluristem Therapeutics Inc., now Pluri Inc., develops PLX cell therapies for inflammatory and hematologic conditions, with trials advancing in 2025.

Replace with .

Poseida Therapeutics Inc. (NASDAQ: PSTX)
Description: Poseida Therapeutics develops allogeneic CAR-T therapies, with P-BCMA-ALLO1 in Phase 1 for multiple myeloma, leveraging its non-viral gene editing platform in 2025.

Praxis Precision Medicines Inc. (NASDAQ: PRAX)
Description: Praxis Precision Medicines focuses on CNS disorders, with ulixacaltamide in Phase 3 for essential tremor and PRAX-562 for epilepsy advancing toward 2025 milestones.

Precision BioSciences Inc. (NASDAQ: DTIL)
Description: Precision BioSciences uses ARCUS® gene editing, with PBGENE-HBV in Phase 1 for hepatitis B and AZER-CEL for leukemia, targeting clinical readouts in 2025.

Progenity Inc. (NASDAQ: BIOR)
Description: Now Biora Therapeutics (ticker changed from PROG in 2022), develops oral biotherapeutics, with its Drug Delivery System in trials for ulcerative colitis, targeting GI precision medicine in 2025.

ProQR Therapeutics N.V. (NASDAQ: PRQR)
Description: ProQR Therapeutics develops RNA therapies for rare diseases, with AX-0810 for cholestatic diseases and AX-1412 for cardiovascular disorders in Phase 2 trials for 2025. Dual listing: Euronext Amsterdam (PRQR.AS).

Protagonist Therapeutics Inc. (NASDAQ: PTGX)
Description: Protagonist Therapeutics develops peptide-based drugs, with rusfertide in Phase 3 for polycythemia vera and JNJ-2113 for psoriasis nearing regulatory submissions in 2025.

Prothena Corporation plc (NASDAQ: PRTA)
Description: Prothena develops protein misfolding therapies, with birtamimab in Phase 3 for AL amyloidosis and PRX019 for Parkinson's advancing with partners in 2025.

Puma Biotechnology Inc. (NASDAQ: PBYI)
Description: Puma Biotechnology markets NERLYNX® for HER2+ breast cancer, with trials for alisertib in lung and breast cancers targeting expanded indications in 2025.

PureTech Health plc (NASDAQ: PRTC)
Description: PureTech Health develops therapies via subsidiaries, with LYT-200 for AML in Phase 1 and Seaport's SPT-300 for anxiety advancing toward 2025 readouts. Dual listing: London Stock Exchange (PRTC.L).

Pyxis Oncology Inc. (NASDAQ: PYXS)
Description: Pyxis Oncology develops ADCs and immunotherapies, with PYX-201 in Phase 1 for solid tumors and PYX-106 for lung cancer progressing in 2025.

Q32 Bio Inc. (NASDAQ: QTTB)
Description: Q32 Bio develops biologics for autoimmune diseases, with bempikibart in Phase 2 for atopic dermatitis and alopecia areata, eyeing 2025 data.

Radius Health Inc. (NASDAQ: RDUS)
Description: Acquired by Gedeon Richter in 2022, Radius Health markets TYMLOS® for osteoporosis, with expanded women's health applications under Richter in 2025.

Rani Therapeutics Holdings Inc. (NASDAQ: RANI)
Description: Rani Therapeutics develops oral biologics delivery, with RT-111 (ustekinumab biosimilar) in Phase 1 for psoriasis, targeting needle-free delivery in 2025.

Rapport Therapeutics Inc. (NASDAQ: RAPT)
Description: Rapport Therapeutics develops CNS therapies, with RAP-219 in Phase 1 for focal epilepsy and chronic pain, advancing toward 2025 proof-of-concept data.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)
Description: Regeneron markets EYLEA® for eye diseases and LIBTAYO® for cancer, with odronextamab for lymphomas and fianlimab for melanoma in late-stage trials for 2025.

REGENXBIO Inc. (NASDAQ: RGNX)
Description: REGENXBIO develops AAV gene therapies, with RGX-314 in Phase 3 for wet AMD and RGX-202 for Duchenne muscular dystrophy targeting 2025 approvals.

Relay Therapeutics Inc. (NASDAQ: RLAY)
Description: Relay Therapeutics uses computational drug design, with RLY-2608 in Phase 1 for PI3Kα-mutated breast cancer, aiming for 2025 clinical milestones.

Repligen Corporation (NASDAQ: RGEN)
Description: Repligen provides bioprocessing solutions, with its filtration and chromatography systems supporting biotech manufacturing scale-ups in 2025.

Repare Therapeutics Inc. (NASDAQ: RPTX)
Description: Repare Therapeutics develops synthetic lethality therapies, with lunresertib in Phase 1/2 for ovarian and lung cancers, targeting 2025 combination therapy data. Dual listing: Toronto Stock Exchange (RPT.TO).

Replimune Group Inc. (NASDAQ: REPL)
Description: Replimune develops oncolytic immunotherapies, with RP1 in Phase 2 for melanoma and RP2 for uveal melanoma, targeting regulatory filings by 2025.

ResMed Inc. (NYSE: RMD)
Description: ResMed markets AirSense™ for sleep apnea and cloud-connected ventilators, expanding digital health integrations for respiratory care in 2025. Dual listing: Australian Securities Exchange (RMD.AX).

Travere Therapeutics Inc. (NASDAQ: TVTX)
Description: Formerly Retrophin Inc. (ticker changed from RTRX in 2020), markets THIOLA® for cystinuria and sparsentan in Phase 3 for FSGS and IgA nephropathy, nearing approvals in 2025.

Revolution Medicines Inc. (NASDAQ: RVMD)
Description: Revolution Medicines develops RAS-targeted therapies, with RMC-6236 in Phase 1 for KRAS-mutated cancers, aiming for broad oncology impact in 2025.

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL)
Description: Rigel Pharmaceuticals markets TAVALISSE® for ITP and REZLIDHIA® for AML, with its kinase inhibitor pipeline growing in 2025.

Rocket Pharmaceuticals Inc. (NASDAQ: RCKT)
Description: Rocket Pharmaceuticals develops gene therapies, with RP-L201 in Phase 2 for LAD-I and RP-A501 for Danon disease, targeting rare disease cures in 2025.

Roivant Sciences Ltd. (NASDAQ: ROIV)
Description: Roivant Sciences advances therapies via Vants, with brepocitinib for dermatomyositis and tapinarof for psoriasis in late-stage trials for 2025 launches.

Sage Therapeutics Inc. (NASDAQ: SAGE)
Description: Sage Therapeutics markets ZULRESSO® for postpartum depression, with zuranolone approved for MDD in 2023 and trials for PPD expanding in 2025.

Sana Biotechnology Inc. (NASDAQ: SANA)
Description: Sana Biotechnology develops engineered cell therapies, with SC291 in Phase 1 for B-cell malignancies, advancing hypoimmune platforms in 2025.

Sangamo Therapeutics Inc. (NASDAQ: SGMO)
Description: Sangamo Therapeutics pioneers genomic medicines, with ST-920 in Phase 1/2 for Fabry disease and zinc finger therapies for hemophilia advancing in 2025.

Sarepta Therapeutics Inc. (NASDAQ: SRPT)
Description: Sarepta markets EXONDYS 51® for DMD, with SRP-9001 in Phase 3 for broader DMD genotypes, eyeing approvals in 2025.

Scholar Rock Holding Corporation (NASDAQ: SRRK)
Description: Scholar Rock develops TGFβ inhibitors, with apitegromab in Phase 3 for SMA and SRK-439 for obesity in preclinical stages for 2025.

Sculptor Capital Management Inc. (NYSE: SCU)
Description: Sculptor Capital Management invests in biotech through hedge funds, supporting early-stage medical tech innovations with capital in 2025. (Note: Acquired by Rithm Capital in 2023, ticker retained for tracking.)

Seagen Inc. (NASDAQ: SGEN)
Description: Acquired by Pfizer in 2023, Seagen markets ADCETRIS® for lymphomas and PADCEV® for bladder cancer, with ADC platforms expanding under Pfizer in 2025. (Note: Delisted, but SGEN ticker may still be referenced.)

Cartesian Therapeutics Inc. (NASDAQ: RNAC)
Description: Formerly Selecta Biosciences (ticker changed from SELB in 2023 post-merger), develops ImmTOR®-enhanced gene therapies, with Descartes-08 in Phase 2 for myasthenia gravis in 2025.

Seres Therapeutics Inc. (NASDAQ: MCRB)
Description: Seres markets SER-109 for recurrent C. diff infection, with SER-155 in trials for GvHD, advancing microbiome therapies in 2025.

Carisma Therapeutics Inc. (NASDAQ: CARM)
Description: Formerly Sesen Bio (ticker changed from SESN in 2023 post-merger), develops CAR-M therapies, with CT-0508 in Phase 1 for HER2+ solid tumors in 2025.

Shattuck Labs Inc. (NASDAQ: STTK)
Description: Shattuck Labs develops Agonist Redirected Checkpoint therapies, with SL-172154 in Phase 1 for ovarian cancer, targeting dual immune activation in 2025.

Shionogi & Co. Ltd. (Tokyo: 4507)
Description: Shionogi markets XOFLUZA® for influenza and advances cefiderocol for bacterial infections, with a growing global biotech presence in 2025. Dual listing: OTC (SGIOY).

SIGA Technologies Inc. (NASDAQ: SIGA)
Description: SIGA Technologies markets TPOXX® for smallpox, with expanded biodefense contracts and antiviral research growing in 2025.

Silence Therapeutics plc (NASDAQ: SLN)
Description: Silence Therapeutics develops siRNA therapies, with SLN360 in Phase 2 for cardiovascular disease and SLN124 for thalassemia, advancing in 2025. Dual listing: London Stock Exchange (SLN.L).

Sorrento Therapeutics Inc. (OTC: SRNEQ)
Description: Sorrento Therapeutics filed for bankruptcy in 2023 (ticker changed from SRNE to SRNEQ), develops CAR-T and antibody therapies, with sofusa lymphatic delivery in trials for cancer in 2025.

Sotera Health Company (NASDAQ: SHC)
Description: Sotera Health provides sterilization and lab services for biotech, with Sterigenics® and Nordion® units supporting medical device production in 2025.

Spark Therapeutics Inc. (NASDAQ: ONCE)
Description: Acquired by Roche in 2019, Spark markets LUXTURNA® for retinal dystrophy and advances hemophilia gene therapies under Roche in 2025. (Note: Delisted, but ONCE ticker may still be referenced.)

Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI)
Description: Spectrum markets ROLONTIS® for neutropenia, with its oncology pipeline refocused on niche markets in 2025 post-2023 restructuring.

SpringWorks Therapeutics Inc. (NASDAQ: SWTX)
Description: SpringWorks markets OGSIVEO® for desmoid tumors, with mirdametinib in Phase 2 for NF1-PN, targeting rare cancers in 2025.

Spero Therapeutics Inc. (NASDAQ: SPRO)
Description: Spero Therapeutics develops antibiotics, with tebipenem HBr in Phase 3 for cUTI and SPR720 for NTM infections, addressing resistance in 2025.

Stoke Therapeutics Inc. (NASDAQ: STOK)
Description: Stoke Therapeutics develops antisense therapies, with STK-001 in Phase 2 for Dravet syndrome and STK-002 for optic atrophy in 2025.

Summit Therapeutics Inc. (NASDAQ: SMMT)
Description: Summit Therapeutics develops ridinilazole for C. diff infection and ivonescimab for lung cancer, with Phase 3 trials advancing in 2025.

Supernus Pharmaceuticals Inc. (NASDAQ: SUPN)
Description: Supernus markets QELBREE® for ADHD and TROKENDI XR® for epilepsy, with a CNS pipeline expanding in pediatric indications in 2025.

Surface Oncology Inc. (NASDAQ: SURF)
Description: Acquired by Coherus BioSciences in 2023, Surface develops SRF388 for liver cancer and SRF114 for solid tumors, enhancing Coherus's oncology portfolio in 2025.

Sutro Biopharma Inc. (NASDAQ: STRO)
Description: Sutro Biopharma develops ADCs and bispecifics, with STRO-002 in Phase 1 for ovarian cancer, leveraging its cell-free protein synthesis in 2025.

Syros Pharmaceuticals Inc. (NASDAQ: SYRS)
Description: Syros develops gene control therapies, with tamibarotene in Phase 3 for MDS and SY-5609 for pancreatic cancer in trials for 2025.

Takeda Pharmaceutical Company Limited (NYSE: TAK)
Description: Takeda markets ENTYVIO® for IBD and TAKHZYRO® for HAE, with a broad pipeline in oncology and rare diseases advancing in 2025. Dual listing: Tokyo Stock Exchange (4502.T).

Talaris Therapeutics Inc. (NASDAQ: TRML)
Description: Now Tourmaline Bio (ticker changed from TALS in 2023 post-restructuring), develops FCR001 for transplant tolerance and TRB-101 for autoimmune diseases in 2025.

Tandem Diabetes Care Inc. (NASDAQ: TNDM)
Description: Tandem markets t:slim X2™ insulin pumps, with Control-IQ® integrations enhancing diabetes management tech in 2025.

Taysha Gene Therapies Inc. (NASDAQ: TSHA)
Description: Taysha develops AAV therapies, with TSHA-120 for GAN and TSHA-102 for Rett syndrome in Phase 1/2 trials aiming for 2025 milestones.

Teladoc Health Inc. (NYSE: TDOC)
Description: Teladoc provides telemedicine platforms, integrating AI-driven diagnostics and chronic care management for biotech synergies in 2025.

Terns Pharmaceuticals Inc. (NASDAQ: TERN)
Description: Terns develops small molecule drugs, with TERN-701 in Phase 1 for CML and TERN-601 for obesity, targeting metabolic diseases in 2025.

TherapeuticsMD Inc. (NASDAQ: TXMD)
Description: TherapeuticsMD markets ANNOVERA® for contraception and IMVEXXY® for menopause, with women's health innovations continuing in 2025.

Theravance Biopharma Inc. (NASDAQ: TBPH)
Description: Theravance markets YUPELRI® for COPD, with ampreloxetine in Phase 3 for neurogenic orthostatic hypotension advancing in 2025.

Thermo Fisher Scientific Inc. (NYSE: TMO)
Description: Thermo Fisher provides biotech tools like sequencing platforms and reagents, driving drug discovery and diagnostics in 2025.

Titan Pharmaceuticals Inc. (NASDAQ: TTNP)
Description: Titan develops ProNeura® implants, with Probuphine® for opioid dependence and new candidates for chronic diseases in trials for 2025.

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)
Description: Tonix develops TNX-102 SL for fibromyalgia and TNX-1300 for cocaine intoxication, with Phase 3 trials progressing in 2025.

Tracon Pharmaceuticals Inc. (NASDAQ: TCON)
Description: Tracon develops envafolimab for sarcoma and TRC102 for lung cancer, with Phase 2 trials targeting niche oncology markets in 2025.

Translate Bio Inc. (NASDAQ: TBIO)
Description: Acquired by Sanofi in 2021, Translate advances mRNA therapies like MRT5005 for cystic fibrosis, enhancing Sanofi's rare disease portfolio in 2025. (Note: Delisted, but TBIO ticker may still be referenced.)

Trillium Therapeutics Inc. (NASDAQ: TRIL)
Description: Acquired by Pfizer in 2021, Trillium advances CD47-targeted therapies like TTI-622 for hematologic cancers, integrated into Pfizer's oncology lineup in 2025. (Note: Delisted, but TRIL ticker may still be referenced.)

Trinity Biotech plc (NASDAQ: TRIB)
Description: Trinity Biotech develops diagnostics for diabetes and infectious diseases, with rapid HIV tests and CGM tech expanding in 2025.

TScan Therapeutics Inc. (NASDAQ: TCRX)
Description: TScan develops TCR-T therapies, with TSC-100 and TSC-101 in Phase 1 for AML and MDS, targeting post-transplant relapse in 2025.

Turning Point Therapeutics Inc. (NASDAQ: TPTX)
Description: Acquired by Bristol Myers Squibb in 2022, Turning Point markets repotrectinib for ROS1+ NSCLC, enhancing BMS's precision oncology in 2025. (Note: Delisted, but TPTX ticker may still be referenced.)

Twist Bioscience Corporation (NASDAQ: TWST)
Description: Twist Bioscience provides synthetic DNA for biotech, with its silicon-based platform supporting drug discovery and antibody development in 2025.

UCB S.A. (Euronext Brussels: UCB)
Description: UCB markets CIMZIA® for autoimmune diseases and BIMZELX® for psoriasis, with a neurology and immunology pipeline growing in 2025. Dual listing: OTC (UCBJY).

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)
Description: Ultragenyx markets Crysvita® for XLH and Mepsevii® for MPS VII, with gene therapies like UX701 for Wilson disease in trials for 2025.

UniQure N.V. (NASDAQ: QURE)
Description: UniQure markets AMT-061 for hemophilia B, with AMT-130 for Huntington's disease in Phase 1/2 trials targeting 2025 milestones.

Unity Biotechnology Inc. (NASDAQ: UBX)
Description: Unity develops senolytic therapies, with UBX1325 in Phase 2 for diabetic macular edema, targeting age-related diseases in 2025.

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)
Description: Vanda markets HETLIOZ® for sleep disorders and FANAPT® for schizophrenia, with tradipitant in trials for gastroparesis in 2025.

Vaxart Inc. (NASDAQ: VXRT)
Description: Vaxart develops oral vaccines, with its norovirus and COVID-19 candidates in Phase 2 trials, leveraging its tablet-based platform in 2025.

VBI Vaccines Inc. (NASDAQ: VBIV)
Description: VBI markets Sci-B-Vac® for hepatitis B, with VBI-2601 in trials for HBV and glioblastoma vaccines advancing in 2025.

VBL Therapeutics (NASDAQ: VB-111)
Description: VBL develops VB-111 for ovarian cancer and glioblastoma, with Phase 3 trials targeting vascular disruption in solid tumors for 2025.

Veracyte Inc. (NASDAQ: VCYT)
Description: Veracyte provides genomic diagnostics, with Afirma® for thyroid cancer and Decipher® for prostate cancer expanding precision medicine in 2025.

Vera Therapeutics Inc. (NASDAQ: VERA)
Description: Vera develops atacicept for IgA nephropathy and MAU868 for BK virus in transplant patients, with Phase 2/3 trials progressing in 2025.

Verastem Inc. (NASDAQ: VSTM)
Description: Verastem develops RAS pathway inhibitors, with avutometinib and defactinib in Phase 2 for low-grade serous ovarian cancer, targeting 2025 approvals.

Vericel Corporation (NASDAQ: VCEL)
Description: Vericel markets MACI® for cartilage repair and Epicel® for burns, with NexoBrid® expanding its regenerative medicine portfolio in 2025.

Verona Pharma plc (NASDAQ: VRNA)
Description: Verona Pharma develops ensifentrine for COPD, with Phase 3 trials completed and potential FDA approval pending in 2025 for respiratory care.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
Description: Vertex markets TRIKAFTA® for cystic fibrosis, with VX-548 for pain and gene editing therapies advancing in 2025.

Verve Therapeutics Inc. (NASDAQ: VERV)
Description: Verve develops base editing therapies, with VERVE-101 in Phase 1 for heterozygous FH, targeting cardiovascular disease in 2025.

Viatris Inc. (NASDAQ: VTRS)
Description: Viatris markets biosimilars and generics, with YUPELRI® for COPD and TYRVAYA® for dry eye enhancing its specialty portfolio in 2025.

Viking Therapeutics Inc. (NASDAQ: VKTX)
Description: Viking develops VK2809 for NASH and VK2735 for obesity, with Phase 2b trials showing promise for metabolic disease treatments in 2025.

Vir Biotechnology Inc. (NASDAQ: VIR)
Description: Vir develops VIR-7831 for hepatitis B and tobevibart for HIV, with Phase 2/3 trials advancing infectious disease solutions in 2025.

Viridian Therapeutics Inc. (NASDAQ: VRDN)
Description: Viridian develops VRDN-001 for thyroid eye disease, with Phase 3 trials underway and potential approvals targeted for 2025.

Vistagen Therapeutics Inc. (NASDAQ: VTGN)
Description: Vistagen develops PH94B for anxiety and PH10 for depression, with Phase 3 trials advancing rapid-acting neuropsychiatric therapies in 2025.

Viveve Medical Inc. (NASDAQ: VIVE)
Description: Viveve markets radiofrequency devices for women's health, with Viveve System® expanding into sexual dysfunction treatments in 2025.

Vivos Therapeutics Inc. (NASDAQ: VVOS)
Description: Vivos markets oral appliances for sleep apnea, with its Vivos Method gaining traction in non-invasive sleep solutions in 2025.

Voyager Therapeutics Inc. (NASDAQ: VYGR)
Description: Voyager develops AAV gene therapies, with VY-HTT01 for Huntington's and VY-SOD102 for ALS in preclinical stages for 2025 trials.

Wave Life Sciences Ltd. (NASDAQ: WVE)
Description: Wave develops stereopure oligonucleotides, with WVE-003 for Huntington's and WVE-N531 for DMD in Phase 1/2 trials in 2025.

Werewolf Therapeutics Inc. (NASDAQ: HOWL)
Description: Werewolf develops cytokine therapies, with WTX-124 in Phase 1 for solid tumors, leveraging its PREDATOR™ platform in 2025.

X4 Pharmaceuticals Inc. (NASDAQ: XFOR)
Description: X4 markets XOLREMDI™ for WHIM syndrome, with trials expanding to chronic neutropenia in 2025.

XBiotech Inc. (NASDAQ: XBIT)
Description: XBiotech develops IL-1α antibodies, with bermekimab in trials for inflammatory diseases and oncology, targeting niche markets in 2025.

Xencor Inc. (NASDAQ: XNCR)
Description: Xencor develops XmAb® bispecifics, with vibecotamab for AML and plamotamab for lymphoma in Phase 1 trials advancing in 2025.

Xeris Biopharma Holdings Inc. (NASDAQ: XERS)
Description: Xeris markets Gvoke® for hypoglycemia, with XP-8121 for endocrine disorders in trials using its XeriSol™ platform in 2025.

XOMA Corporation (NASDAQ: XOMA)
Description: XOMA acquires royalty interests in biotech, with its portfolio including assets from Novartis and Takeda, generating revenue in 2025.

Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)
Description: Y-mAbs markets DANYELZA® for neuroblastoma, with omburtamab in trials for CNS metastasis, targeting pediatric cancers in 2025.

Zai Lab Limited (NASDAQ: ZLAB)
Description: Zai Lab markets ZEJULA® for ovarian cancer in China, with a pipeline advancing oncology and autoimmune therapies globally in 2025. Dual listing: Hong Kong Stock Exchange (9688.HK).

Zealand Pharma A/S (NASDAQ: ZEAL)
Description: Zealand Pharma develops peptide therapies, with dasiglucagon for hypoglycemia and glepaglutide for short bowel syndrome in late-stage trials in 2025. Dual listing: Copenhagen Stock Exchange (ZEAL.CO).

Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL)
Description: Zentalis develops ZN-c3 for solid tumors and ZN-d5 for lymphoma, with Phase 2 trials targeting Wee1 and BCL-2 inhibition in 2025.

Zimmer Biomet Holdings Inc. (NYSE: ZBH)
Description: Zimmer Biomet markets orthopedic implants and ROSA® robotics, with smart implants enhancing surgical precision in 2025.

Alaunos Therapeutics Inc. (NASDAQ: TCRT)
Description: Formerly ZIOPHARM Oncology (ticker changed from ZIOP in 2022), develops TCR-T therapies, with its Sleeping Beauty platform in trials for solid tumors in 2025.

Zogenix Inc. (NASDAQ: ZGNX)
Description: Acquired by UCB in 2022, Zogenix markets FINTEPLA® for Dravet syndrome, with UCB expanding its epilepsy portfolio in 2025. (Note: Delisted, but ZGNX ticker may still be referenced.)

Zymeworks Inc. (NASDAQ: ZYME)
Description: Zymeworks develops zanidatamab for HER2+ cancers and ZW49 for solid tumors, with Phase 2/3 trials advancing bispecific antibody platforms in 2025.

TOP